期刊档案 · Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
Current Molecular Pharmacology
ISSN 1874-4672 · eISSN 1874-4702 · KEAI PUBLISHING LTD · United Arab Emirates
Current Molecular Pharmacology 中科院 生物学 4区（2025 年升级版），影响因子 7.11，完全开放获取，收取 APC，金额未公布，近 24 个月 17 篇文章投稿到接收中位 99 天，2025 年发文 40 篇，SCIE、Scopus 收录。
研究范围
研究范围与定位
Current Molecular Pharmacology 由 KEAI PUBLISHING LTD 出版，属中科院生物学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Ion channel regulation and function、MicroRNA in disease regulation、Neuroscience and Neuropharmacology Research 等主题的论文，这 3 个主题约占 18.1%，主导子领域为 Molecular Biology。（根据 OpenAlex 主题统计与中科院分区数据生成）
Volumes 1-17 of Current Molecular Pharmacology published by Bentham Science can be accessed here: https://www.benthamscience.com/journal/98. Current Molecular Pharmacology is a peer-reviewed international journal dedicated to publishing the latest advancements in cellular and molecular pharmacology. It emphasizes the mechanisms of action of novel drugs under development, innovative pharmacological technologies, and the application of genomics, proteomics, and metabonomics to drug action. Additionally, the journal explores how the study of drug actions at the cellular and molecular level provides insights into normal biological functions, fostering a deeper understanding of both therapeutic interventions and fundamental biological processes. This journal contains five sections:Section A (Mechanism of Action of Novel Drugs): This section focuses on understanding the mechanisms by which novel drugs under development exert their effects, covering molecular targets, pharmacodynamic and pharmacokinetic studies, structure-activity relationships (SAR), and preclinical and clinical insights into drug mechanisms.Section B (Innovative Pharmacological Technologies): This section highlights advances in pharmacological technologies and methodologies, including high-throughput screening, drug delivery systems, nanotechnology, computational pharmacology, AI-driven drug discovery, and novel experimental models for drug testing.Section C (Cell Signaling and Transduction Pathways): This section explores the analysis of cellular signaling and transduction pathways relevant to drug action, including key pathways, receptor-ligand interactions, cross-talk between pathways, and pharmacological modulation of signaling networks.Section D (Omics Applications in Pharmacology): This section focuses on the integration of genomics, proteomics, and metabonomics in understanding drug action, covering pharmacogenomics, proteomic profiling of drug responses, metabonomic studies of drug metabolism and toxicity, and multi-omics approaches to drug discovery.Section E (Drug Actions and Biological Functions): This section examines how drug actions at the cellular and molecular level illuminate normal biological functions, including drug-induced modulation of physiological processes, insights into disease mechanisms, and translational research linking molecular pharmacology to clinical outcomes.Editorial Board
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Ion channel regulation and functionBiochemistry, Genetics and Molecular Biology6.5%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology6%
- Neuroscience and Neuropharmacology ResearchNeuroscience5.6%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology5%
- Cancer, Lipids, and MetabolismBiochemistry, Genetics and Molecular Biology5%
- Peroxisome Proliferator-Activated ReceptorsBiochemistry, Genetics and Molecular Biology4.8%
- Computational Drug Discovery MethodsComputer Science4.5%
- Stress Responses and CortisolNeuroscience4.5%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）生物学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 生物学 | 4 区 |
| 小类 | 生化与分子生物学BIOCHEMISTRY & MOLECULAR BIOLOGY | 4 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 4 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）生物学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 生物学 | 2 区 |
| 小类 | 生化与分子生物学BIOCHEMISTRY & MOLECULAR BIOLOGY | 3 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 3 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）生物学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 生物学 | 4 区 |
| 小类 | 生化与分子生物学BIOCHEMISTRY & MOLECULAR BIOLOGY | 4 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 4 区 |
Top 期刊：否综述期刊：否
数据库收录
SCIEScopusLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 7.11LetPub ·
- 影响因子（出版商公布）
- 7.2出版商官网 ·
- CiteScore 2026-06
- 7.8LetPub ·
- SJR 2026-06
- 1.02LetPub ·
- SNIP 2026-06
- 0.92LetPub ·
- h-index
- 34LetPub ·
- h-index
- 60OpenAlex ·
- i10-index
- 451OpenAlex ·
- 两年平均被引
- 8.51OpenAlex ·
- 自引率
- 0%LetPub ·
- Gold OA 文章占比
- 58.16%LetPub ·
发文规模
- 年文章数
- 25LetPub ·
逐年发文量 OpenAlex 统计 · 累计 921 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 36 | 36 | 9 |
| 2025 | 40 | 28 | 265 |
| 2024 | 48 | 47 | 781 |
| 2023 | 57 | 47 | 755 |
| 2022 | 87 | 4 | 1,019 |
| 2021 | 103 | 4 | 1,443 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 Crossref 登记的稿件日期 · 至
99 天投稿到接收中位数 · P25–P75 70 天 – 112 天
- 接收到上线
- 中位数 59 天（17 篇）
- 投稿到上线
- 中位数 155 天
- 样本
- 17 篇有投稿与接收日期的文章（窗口内共 84 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 评审方式
- 单盲同行评审出版商官网
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取LetPub
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| 出版商官网 | 有，金额未公布 | — | — |
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点5 项，摘自作者指南
- 摘要
- ≤ 300 词
- 关键词
- ≥ 3 个
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- Highlights（研究亮点）
- 可选
- 图文摘要
- 可选
接收的文章类型3 种，含篇幅限制
- letterCurrent Molecular Pharmacology publishes:Article TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a s…未说明篇幅
- letter to the editorCurrent Molecular Pharmacology publishes:Article TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a s…未说明篇幅
- opinionCurrent Molecular Pharmacology publishes:Article TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a s…正文 ≤ 12,000 词
官网政策摘录AI 使用、作者资格、利益冲突、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
原文 ↗出版商官网 ·- 作者资格 Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
原文 ↗出版商官网 ·- 利益冲突 Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
原文 ↗出版商官网 ·- 许可与版权 Creative Commons Attribution (CC BY)
Allows users to: distribute and copy the article; create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: gives appropriate credit to the author(s) (with a lin…
原文 ↗出版商官网 ·- 开放获取 KeAi Guide for authors: Open Access
This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party (re)use is defined by the following Creative …
原文 ↗出版商官网 ·- 同行评审 Peer review
Single anonymized review process 模型摘要
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors to determine suitability for publication in this journal. If your submission is deemed suitable, it will typically be sent to a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected will…
原文 ↗出版商官网 ·- 预印本 Preprint sharing
Authors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- KEAI PUBLISHING LTD
- 出版国家或地区
- United Arab Emirates
- 出版语言
- English
- ISSN
- 1874-4672
- 电子版 ISSN
- 1874-4702
常见问题
关于 Current Molecular Pharmacology 的常见问题
Current Molecular Pharmacology 是中科院几区期刊？
2025 年升级版分区表中，Current Molecular Pharmacology 为生物学 4区，小类 生化与分子生物学 / 药学 4 区。2026 年新锐版分区表中为生物学 2区。不同版本与大小类分区不能混用。
Current Molecular Pharmacology 的影响因子是多少？
LetPub 汇总的最新公布影响因子为 7.11，CiteScore 为 7.8，h-index 为 60。
Current Molecular Pharmacology 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）17 篇已发表文章登记的日期，投稿到接收的中位数为 99 天（四分位 70–112 天）。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Current Molecular Pharmacology 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 300 词；关键词：≥ 3 个；参考文献格式：顺序编码制（按引用顺序编号）；Highlights：可选；图文摘要：可选。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Current Molecular Pharmacology 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Current Molecular Pharmacology 被 SCIE、Scopus 收录。
Current Molecular Pharmacology 是开放获取期刊吗？版面费多少？
Current Molecular Pharmacology 为完全开放获取。收取 APC，金额未公布。
来源与更新
本页事实来自 LetPub、OpenAlex、出版商官网；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。